Biologic Therapies in Rheumatoid Arthritis and the Risk of Opportunistic Infections: A Meta-analysis | Zendy

Irene S. Kourbeti | Zendy; Panayiotis D. Ziakas | Zendy; Eleftherios Mylonakis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biologic Therapies in Rheumatoid Arthritis and the Risk of Opportunistic Infections: A Meta-analysis

Author(s) -

Irene S. Kourbeti,

Panayiotis D. Ziakas,

Eleftherios Mylonakis

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu185

Subject(s) - medicine , rheumatoid arthritis , odds ratio , number needed to harm , confidence interval , randomized controlled trial , placebo , meta analysis , pneumonia , relative risk , number needed to treat , pathology , alternative medicine

Biologic agents are increasingly used to treat patients with rheumatoid arthritis (RA). We aimed to review their association with opportunistic infections (OIs), including fungal, viral (with a focus on herpesvirus-related infections), tuberculosis and other mycobacterial infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research